<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04279847</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 57643-103</org_study_id>
    <nct_id>NCT04279847</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms</brief_title>
  <official_title>A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy&#xD;
      of INCB057643 as monotherapy or combination with ruxolitinib for participants with&#xD;
      myelofibrosis and other myeloid neoplasms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Anticipated">November 11, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 11, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>monotherapy and ruxoltinib combination</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment-emergent adverse events</measure>
    <time_frame>Up to approximately 9 months</time_frame>
    <description>Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug monotherapy and in combination with ruxolitinib.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>up to approximately 9 months</time_frame>
    <description>Defined as the proportion of participants with Complete Response or Partial Response when treated with study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Response Rate</measure>
    <time_frame>Week 24</time_frame>
    <description>Defined as the proportion of participants who achieve a protocol defined reduction in Total Symptomatic Score (TSS) relative to baseline as measured by the MPN-SAF TSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anemia response</measure>
    <time_frame>Up to approximately 9 months</time_frame>
    <description>Hemoglobin increase of 1.5 g/dL relative to baseline for any &quot;rolling&quot; 12-week period during the first 24 weeks of treatment, if Transfusion Independent (TI) at baseline or achieving TI for any rolling 12 week period during the first 24 weeks of treatment if Transfusion Dependent (TD) at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Anemia Response</measure>
    <time_frame>Up to approximately 9 months</time_frame>
    <description>The interval from the first onset of anemia response to the earliest date of loss of anemia response that persists for at least 4 weeks or death from any cause for the TI participants at baseline or duration of RBC-TI period for participants achieving RBC-TI for at least 12 consecutive weeks during the first 24 weeks of treatment for the TD participants at baseline, or Mean change from baseline in the hemoglobin value over 12-week treatment periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of red blood cell (RBC) transfusion dependency</measure>
    <time_frame>24 and 48 Weeks</time_frame>
    <description>Defined as the average number of RBC units per participant month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in Spleen Volume</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Defined as percentage of participants with a protocol defined Spleen Volume Reduction (SVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spleen length response</measure>
    <time_frame>Up to approximately 9 months</time_frame>
    <description>Defined as the proportion of participants achieving a protocol defined reduction in spleen length at any visit relative to baseline as measured by palpation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Myelofibrosis</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome</condition>
  <condition>Myeloproliferative Neoplasm</condition>
  <condition>Relapsed or Refractory Primary Myelofibrosis</condition>
  <condition>Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)</condition>
  <arm_group>
    <arm_group_label>INCB057643 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB057643 dose escalation (Part 1) and dose expansion (Part 2: treatment group A).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB057643 Combination with Ruxolitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination arm in dose escalation (Part 1) and dose expansion (Part 2: Treatment Group B)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB057643</intervention_name>
    <description>INCB057643 dose escalation (Part 1) and dose expansion (Part 2).</description>
    <arm_group_label>INCB057643 Combination with Ruxolitinib</arm_group_label>
    <arm_group_label>INCB057643 Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>Ruxolitinib will be administered twice a day using the dose designated as the stable dose at the time of the screening visit for each subject. Acceptable doses are 5 mg BID to 25 mg BID.</description>
    <arm_group_label>INCB057643 Combination with Ruxolitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Relapsed or refractory primary myelofibrosis (MF), secondary MFs (post-polycythemia&#xD;
             vera MF, post- essential thrombocythemia MF) myeloproliferative neoplasm (MPN),&#xD;
             myelodysplastic syndrome (MDS), and myelodysplastic/myeloproliferative neoplasm&#xD;
             overlap syndrome (MDS/MPN)&#xD;
&#xD;
          -  Must not be a candidate for potentially curative therapy, including hematopoietic&#xD;
             stem-cell transplantation.&#xD;
&#xD;
          -  Willingness to undergo a pretreatment bone marrow biopsy and/or aspirate at&#xD;
             screening/baseline, or archival sample obtained since completion of most recent&#xD;
             therapy.&#xD;
&#xD;
          -  Willingness to avoid pregnancy or fathering children.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior receipt of a BET inhibitor within 5 half-lives of the compound, and/or&#xD;
             experienced BET inhibitor-related AE(s) resulting in dose discontinuation.&#xD;
&#xD;
          -  Receipt of anticancer medications or investigational drugs within the protocol-defined&#xD;
             interval before the first dose of study treatment:&#xD;
&#xD;
        Note: For participants in Part 2, Treatment Group B, ruxolitinib will continue at the&#xD;
        participants' current, ongoing doses. No ruxolitinib washout is needed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>globalmedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama At Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University - Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of Nj</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of North Carolina At Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Cancer Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>L Azienda Ospedaliero-Universitaria Di Bologna Policlinico S. Orsola ? Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi (Aouc)</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS CA Granda Ospedale Maggiore</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2020</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelofibrosis</keyword>
  <keyword>myelodysplastic syndrome</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm overlap syndrome</keyword>
  <keyword>myeloproliferative neoplasm</keyword>
  <keyword>BET protein inhibitor</keyword>
  <keyword>relapsed primary myelofibrosis</keyword>
  <keyword>refractory primary myelofibrosis</keyword>
  <keyword>secondary myelofibrosis</keyword>
  <keyword>post-polycythemia vera myelofibrosis</keyword>
  <keyword>post-essential thrombocythemia myelofibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>INCB057643</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Access to patient level data is not available for this study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

